



► **NEURATRIS - NATIONAL INFRASTRUCTURE FOR BIOLOGY & HEALTH
BIOTHERAPIES FOR NEUROSCIENCES**

NeurATRIS: Translational Infrastructure for Neurosciences

Gathering together over 2000 leading Neuroscientists (researchers, clinicians, engineers), the National Infrastructure NeurATRIS aims at conducting R&D projects throughout the pre-clinical/clinical translational continuum, offering its services to academic, clinicians and industrial partners.

Due to the multidisciplinary nature of translational research programs dedicated to brain disorders, integrating all the necessary preclinical and clinical expertises in one unique national Infrastructure is crucial to propose, test and validate new therapeutic strategies for these pathologies. NeurATRIS, relying on five key partners represents one of the largest concentrations of neurology researchers available in Europe:

I) The Paris Institute for translational Research in Neurosciences, gathering a wealth of scientific, technological and therapeutic expertise's in drug-based therapies of a large panel of brain diseases,

II) The CEA research centres MIRCen, Neurospin, SHFJ, making this an international hub for research and innovation in imaging and biomedical technologies,

III) Two other medium size clinical centres - Henri Mondor and Neurosciences Bicêtre, with a strong expertise in biotherapies for neurodegenerative diseases and pediatric neurology,

IV) The Biotherapies Institute for Rare Disease, a R&D centre promoting the development of innovative gene and cell therapies for various applications and clinical indications.

Organized in one single networked infrastructure, NeurATRIS takes advantage of the resources and skills of the different par-



BCL-3 viral vectors production Lab



BCL-2 Laboratories



Clinical Magnetic Resonance Imaging

tner's preclinical and clinical platforms to:
1/ conduct Technological R&D projects focused on cell and gene therapies, in-vivo assessment of disease processes & therapeutic efficacy, and molecular-based therapies which are implemented to specifically address scientific, technological and medical challenges faced by the translational research in neurology.

2/ trigger strong and durable public/private partnerships as a mean to provide solutions to major bottleneck issues limiting industrial competitiveness by:

I) Developing specific lines of translational research and know-hows in Neuroscience with the aim of discovering and qualifying at the preclinical and clinical level new therapeutic solutions for neurodegenerative and neuropsychiatric disorders,

II) Overcoming the fragmented nature of science by bringing together various specialists of cell, gene and drug-based technologies enabling cross-functional fusion of

skills and expertise in a single structure, as an efficient mean to perform proof of principle and proof of concept studies at the preclinical and clinical level,

III) Offering an easy access to state-of-the-art technological platforms and know-hows through a unique access point along with highly trained personnel to academic, clinical and industrial sectors,

IV) Providing dedicated translational research project managers to follow up external academic or industrial projects through the different platforms. ■

CONTACTS

philippe.hantraye@cea.fr simone.mergui@cea.fr

NEURATRIS HEAD QUARTER:

CEA - MIRCEN

CEA Center of Fontenay,
18 route du panorama,
92264 Fontenay Aux Roses, France
Phone: 00 33 1 46549364
www.neuratris.fr

► NeurATRIS is a strong national entity of EATRIS, the European Advanced Translational Research Infrastructure in Medicine (ESFRI), as the sole European Translational Research Infrastructure dedicated to Neurosciences and is funded by the "Investissements d'Avenir - Infrastructure Nationale en Biologie et Santé 2012" call (Total funding: € 28 million).

PUBLIC COMMUNIQUÉ